EGFR and non-small cell lung carcinoma: The POLESTAR study which evaluated aumolertinib, another 3rd generation TKI in locally advanced NSCLC, also noted efficacy results comparable to the LAURA trial, thus confirming the efficacy of EGFR inhibition in this setting (25).